MedTrace Logo

Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer

NCT02485548 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2015-06-30

No results posted yet for this study

Summary

This study is a multicenter phase Ⅲ trial. The objective is to compare the efficacy and toxicity of cisplatin plus raltitrexed or 5-fluorouracil in concurrence with IMRT for patients with locoregionally advanced head and neck squamous cell cancer.

Conditions

  • Head and Neck Squamous Cell Cancer

Interventions

DRUG

Raltitrexed

Patients will receive IMRT and concurrent raltitrexed and cisplatin

DRUG

5-fluorouracil

Patients will receive IMRT and concurrent 5-Fu and cisplatin

DRUG

Cisplatin

All patients will receive concurrent cisplatin.

RADIATION

IMRT

All patients will receive IMRT

Sponsors & Collaborators

  • Affiliated Hospital of Jiangnan University

    collaborator OTHER

  • Changzhou Cancer Hospital of Soochow University

    collaborator OTHER

  • The First Affiliated Hospital with Nanjing Medical University

    collaborator OTHER

  • Northern Jiangsu People's Hospital

    collaborator OTHER

  • The Second Hospital of Nanjing Medical University

    collaborator OTHER

  • Nanjing BenQ Hospital

    collaborator UNKNOWN

  • Jiangsu Cancer Institute & Hospital

    lead OTHER

Principal Investigators

  • Xia He, M.D. · Jiangsu Cancer Institute & Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02485548 on ClinicalTrials.gov